Skip to content

Serotonin-receptor Agonism in Reward Processing

Serotonin-receptor Agonism in Reward Processing

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05357547
Acronym
SARP
Enrollment
63
Registered
2022-05-03
Start date
2022-05-13
Completion date
2023-04-18
Last updated
2023-05-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anhedonia

Keywords

5HT1A receptor, Reward, Emotion, Memory, Buspirone

Brief summary

There is growing animal and human evidence for role of 5HT1A receptor agonism in treating depression and reward deficits. The next step is to translate this evidence directly into humans by characterising the effects of buspirone, as a 5HT1A agonist, on cognitive models of reward and emotional processing. There is a paucity of behavioural evidence for the effect of 5HT1A receptor agonism, using buspirone as a probe, on primary reward processing (e.g. food), effort-based decision making or reward learning. Furthermore, the effects of 5HT1A agonism on non-emotive cognition, such as working memory, has yet to be investigated at a behavioural level in humans. This study will characterise the effects of buspirone, as a probe for 5HT1A receptor agonism, on reward processing in human cognitive models. Furthermore it will examine its role in emotional processing and working memory. This will add to the evidence base of the neurocognitive effects of 5HT1A receptor agonism in humans, which is of relevance to the development of this as a target for future treatment development. The study will be a double blinded, placebo controlled study involving healthy volunteers. Participants will receive a single dose of buspirone and then undergo a battery of psychometric testing to examine reward processing, emotional processing and a memory. Frequent monitoring of temperature and salivary cortisol shall be taken as surrogate markers of pre- and postsynaptic 5HT1A receptor activation.

Interventions

DRUGBuspirone 20mg

Buspirone tablets in opaque capsule. Used as probe for 5HT1A agonism

DRUGPlacebo comparator

Lactose-sucrose tablets in opaque capsule

Sponsors

University of Oxford
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
Yes

Inclusion criteria

* Participant is willing and able to give informed consent for participation in the research * Male or female * Body mass index in the range of 18 to 30 * Not currently taking any medications (except for contraception)

Exclusion criteria

* • Any current Axis 1 The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) psychiatric disorder * Any previous episode of a severe mental illness, * A first degree relative diagnosed with Bipolar Affective Disorder Type 1 or Schizophrenia * Body Mass Index outside the range of 18 to 30 inclusive * Any significant current medical condition likely to interfere with conduct of the study or analysis of data (epilepsy, renal disease, hepatic disease, myasthenia gravis, acute closed-angle glaucoma) * Current use of psychoactive and / or medically significant medication as judged by a study medic, whether prescribed or bought over the counter (the contraceptive pill, the Depo-Provera injection or the progesterone implant will not result in exclusion) * Past history of dependence to illicit substances, and any consumption of illicit substances in the three months prior to the study * Currently pregnant or breast feeding * Known lactase deficiency or any other problem absorbing lactose, galactose, or glucose * Participation in a study using the same tasks in the last year * Any physical (including visual and auditory) or language impairment that would make complying with the study protocol challenging. This includes any taste/olfactory disturbance e.g. secondary to Covid-19 infection

Design outcomes

Primary

MeasureTime frameDescription
Primary reward perceptionOn day of intervention (30 minutes pre-intervention and post-intervention (60 - 180 minutes))Visual Analogue Scale of anticipation of pleasure, intensity of taste and pleasure experienced when tasting one of four 4 tastes representing a primary reward stimulus processing.
Effort based reward task:On day of intervention ( 90 - 180 minutes post intervention)offer acceptance based upon effort required (grip force on hand held dynamometer) to obtain outcome and success rate in expending correct amount of effort required for reward
Changes in reward sensitivityOn day of intervention (90 - 180 minutes post intervention)Sensitivity to reward as measured by the Probabilistic Instrumental Learning Task (Amount won, amount lost, total monetary amount earned , proportion of participants choosing the correct symbol in win and loss trials)

Secondary

MeasureTime frameDescription
Change in N-back task performanceOn day of intervention (90 - 180 minutes post intervention)Accuracy on the N-back task
Change in Auditory Verbal Learning TaskOn day of intervention (90 - 180 minutes post intervention)Accuracy on AVLT (number of items recalled across blocks)
Changes in recognition of emotional facial expressionsOn day of intervention (90 - 180 minutes post intervention)Accuracy of emotion labels (e.g. disgusted face) assigned by participants to expressive faces which have appeared on a computer screen for a period of 500ms.
Temperature measurementOn day of intervention (30 minutes pre-intervention, at time of intervention, at 30 minute intervals thereafter)Temperature measurement at 30 minute intervals as surrogate of 5HT1A receptor activation
Temporal Experience of Pleasure scale (TEPS)On screening day and testing dayMeasure of anticipatory and consummatory aspects of reward (state measure). 18 item questionnaire (10 items for anticipatory; 8 items for consummatory). Each item scored on 6 point Likert scale (1 = very false for me to 6 = very true for me). Lower score indicates greater anhedonia.
Cortisol measurementOn day of intervention (30 minutes pre-intervention, at time of intervention, at 30 minute intervals thereafter)Salivary cortisol measurement at 30 minute intervals as surrogate of 5HT1A receptor activation
Changes in categorisation of emotional wordsOn day of intervention (90 - 180 minutes post intervention)Accuracy to categorise positive and negative descriptor words
Changes in recall of emotional wordsOn day of intervention (90 - 180 minutes post intervention)Number of words accurately recalled

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 30, 2026